-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QSaWQO+5P4sPn5UXhVJEKMCBQr8rmVSOIlrvpMixqrzoiZ72MyTZVLZ+9Y6qsrFX zRzJ94EM1XG86RW2/heg2A== 0000950138-09-000161.txt : 20090227 0000950138-09-000161.hdr.sgml : 20090227 20090227103605 ACCESSION NUMBER: 0000950138-09-000161 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090227 ITEM INFORMATION: Other Events FILED AS OF DATE: 20090227 DATE AS OF CHANGE: 20090227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Stereotaxis, Inc. CENTRAL INDEX KEY: 0001289340 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943120386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50884 FILM NUMBER: 09640192 BUSINESS ADDRESS: STREET 1: 4041 FOREST PARK AVENUE CITY: ST.LOUIS STATE: MO ZIP: 63108 BUSINESS PHONE: 314-615-6940 MAIL ADDRESS: STREET 1: 4041 FOREST PARK AVENUE CITY: ST.LOUIS STATE: MO ZIP: 63108 8-K 1 form8k.htm

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported)

   February 27, 2009

 

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-50884

94-3120386

(Commission File Number)

(IRS Employer Identification No.)

 

4320 Forest Park Avenue, Suite 100, St. Louis, Missouri

63108

(Address of Principal Executive Offices)

(Zip Code)

 

 

(314) 678-6100

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

Item 8.01.   Other Events.

 

On February 27, 2009, Biosense Webster, Inc., announced that the U.S. Food and Drug Administration has approved for marketing its NAVISTAR® RMT THERMOCOOL® Catheter for use with the Stereotaxis NIOBE® platform. Stereotaxis (NASDAQ: STXS) (“Stereotaxis” or the “Company”) has partnered with Biosense Webster, Inc. in the development of ablation catheters used with its NIOBE® Magnetic Navigation System. The NAVISTAR® RMT THERMOCOOL® Catheter for radiofrequency (RF) ablation is used with the NIOBE® Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment.

“NAVISTAR” and “THERMOCOOL” are registered trademarks of Biosense Webster, and “NIOBE” is a registered trademark of Stereotaxis.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

STEREOTAXIS, INC.

 

 

 

Date: February 27, 2009

By:

/s/ James M. Stolze

 

Name:

James M. Stolze

 

Title:

Vice President and Chief Financial Officer

 

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----